# US 2026/0097135 A1 · MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS (oHSV) AND METHODS OF USE THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097135 A1
- Document ID: US20260097135A1
- Status: Published application
- Kind: A1
- Application number: 19/114,912
- Filed: 2023-09-26
- Published: 2026-04-09
- Earliest claimed: 2022-09-26
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: Robert L. Martuza; Samuel D. Rabkin; Dipongkor Saha; Nusrat Jahan
- Web page: https://patentgrep.com/patent/US20260097135A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 38/208: {IL-12}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 15/86: Viral vectors
- A61K 35/763: Herpes virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2710/16621: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/16622: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C12N 2710/16662: by genetic engineering
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer/promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).

## Claims

### Claim 1

An expression cassette comprising an enhancer sequence comprising two or more DR2 repeat sequence units (CGCTCCTCCCCC (SEQ ID NO:7) inserted upstream of a promoter, preferably within 500, 250, 200, or 100 nucleotides of the promoter, and optionally a transgene operably linked to the promoter.

### Claim 2 (depends on 1)

The expression cassette of claim 1, wherein the enhancer sequence comprises from six to 24 DR2 repeat sequence units (CGCTCCTCCCCC (SEQ ID NO:7).

### Claim 3 (depends on 1)

The expression cassette of claim 1, wherein the enhancer sequence comprises:
(SEQ ID NO: 4)
CTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCG
CTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCC
CCGCTCCTCCCCCCGCTCCTCCCCCCCCCGCTCCCGCGGCCCCGC
CCCCAACGCCCGCTCCTCCCCCCGCTCCCGCGGCCCCGCCC,
or
(SEQ ID NO: 5)
CTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCG
CTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCC
CCGCTCCTCCCCCCGCTCCTCCCCCCCCCGCTCCCGCGGCCCCGC
CCCCAACGCCCGCTCCTCCCCCCGCTCCCGCGGCCCCGCCCCCAA
CGCCCGCCGCGCGCGCGCACGCCGCCCTTGACTCACGGGGATTTC
CAAGTCTCCACCCCATTGACGTC,
or
(SEQ ID NO: 15)
ATCCCCCGCTCCTCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCT
CCTCCCCCCGCTCCTCCCCCGCTCCTCCCCCCGCTCCTCCCCCCG
CTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCC
CCGCTCCTCCCCCCGCTCCCGCGGCCCCGCCCCCAACGCCCGCTC
CTCCCCCCGCTCCCGCGGCCCCGCCCCCAACGCCCGCCGCGCGCG
CGCACGCCGCCCGGACCGCCGCCCGCCTTTTTTGCGCGCCGCCCC
GCCCGCGGGGGGCCCGGGCTGCGCCGCCGCGCTTTAAAGGGCCGC
GCGCGACCCCCGGGGGGTGTGTTTCGGGGGGGGCCCGTTTCTCCC
GCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCC
CCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCT
CCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCT
CCCGCGGCCCCGCCCCCAACGCCCGCTCCTCCCCCCGCTCCCGCG
GCCCCGCCCCCAACGCCCGCCGCGCGCGCGCACGCCGCCCT.

### Claim 4 (depends on 1)

The expression cassette of claim 1, wherein the expression cassette is in a plasmid, cosmid, or viral vector.

### Claim 5 (depends on 4)

The expression cassette of claim 4, wherein the viral vector is selected from the group consisting of recombinant retroviruses, adenovirus, adeno-associated virus, alphavirus, oncoviruses, and lentiviruses.

### Claim 6 (depends on 5)

The expression cassette of claim 5, wherein the oncovirus is a herpes simplex virus.

### Claim 7 (depends on 5)

The expression cassette of claim 5, wherein the herpes simplex virus comprises one or more of: one or more alterations selected from deletion of both copies of γ34.5; deletion of ICP47 and/or Us11 promoter; an inactivating insertion in ICP6; downregulation, tumor-selective expression, and/or specific amino acid mutations of γ34.5, ICP47, and/or ICP6; upregulation or tumor-selective expression of Us11; and a reporter gene like GFP or LacZ.

### Claim 8 (depends on 5)

The expression cassette of claim 5, which is in G207, MG18L, Δ68H-6, or G47Δ.

### Claim 9 (depends on 1)

The expression cassette of claim 1 comprising a transgene, optionally wherein the transgene is selected from cytokines, chemokines, complement components and their receptors, immune system accessory molecules, adhesion molecules, adhesion receptor molecules, and adenosine-degrading enzymes.

### Claim 10 (depends on 9)

The expression cassette of claim 9, wherein the cytokine is selected from interleukins, optionally any of interleukins 1-15, preferably IL-12; α, β, or γ-interferons; tumor necrosis factor; granulocyte macrophage colony stimulating factor (GM-CSF); macrophage colony stimulating factor (M-CSF); and granulocyte colony stimulating factor (G-CSF).

### Claim 11 (depends on 9)

The expression cassette of claim 9, wherein the chemokine is selected from B7.1 and B7.2.

### Claim 12 (depends on 9)

The expression cassette of claim 9, wherein the adhesion molecule is selected from ICAM-1, 2, and 3.

### Claim 13 (depends on 9)

The expression cassette of claim 9, wherein the immune system accessory molecule is selected from neutrophil activating protein (NAP), macrophage chemoattractant and activating factor (MCAF), RANTES, and macrophage inflammatory peptides MTP-1a and MTP-1b.

### Claim 14 (depends on 1)

A method of expressing a transgene in a cell, the method comprising contacting the cell with the expression cassette of claim 1, wherein the expression cassette comprises the transgene.

### Claim 15

An oncolytic herpes simplex virus (oHSV) comprising a promoter and an enhancer sequence, wherein the enhancer sequence comprises from six to 24 DR2 repeat sequence units (CGCTCCTCCCCC (SEQ ID NO:7), preferably wherein the enhancer sequence comprises:
(SEQ ID NO: 4)
CTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCG
CTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCC
CCGCTCCTCCCCCCGCTCCTCCCCCCCCCGCTCCCGCGGCCCCGC
CCCCAACGCCCGCTCCTCCCCCCGCTCCCGCGGCCCCGCCC,
or
(SEQ ID NO: 5)
CTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCG
CTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCC
CCGCTCCTCCCCCCGCTCCTCCCCCCCCCGCTCCCGCGGCCCCGC
CCCCAACGCCCGCTCCTCCCCCCGCTCCCGCGGCCCCGCCCCCAA
CGCCCGCCGCGCGCGCGCACGCCGCCCTTGACTCACGGGGATTTC
CAAGTCTCCACCCCATTGACGTC,
or
(SEQ ID NO: 15)
ATCCCCCGCTCCTCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCT
CCTCCCCCCGCTCCTCCCCCGCTCCTCCCCCCGCTCCTCCCCCCG
CTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCC
CCGCTCCTCCCCCCGCTCCCGCGGCCCCGCCCCCAACGCCCGCTC
CTCCCCCCGCTCCCGCGGCCCCGCCCCCAACGCCCGCCGCGCGCG
CGCACGCCGCCCGGACCGCCGCCCGCCTTTTTTGCGCGCCGCCCC
GCCCGCGGGGGGCCCGGGCTGCGCCGCCGCGCTTTAAAGGGCCGC
GCGCGACCCCCGGGGGGTGTGTTTCGGGGGGGGCCCGTTTCTCCC
GCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCC
CCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCT
CCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCT
CCCGCGGCCCCGCCCCCAACGCCCGCTCCTCCCCCCGCTCCCGCG
GCCCCGCCCCCAACGCCCGCCGCGCGCGCGCACGCCGCCCT.

### Claim 16 (depends on 15)

The oHSV of claim 15, further comprising a transgene, optionally wherein the transgene is selected from cytokines, chemokines, complement components and their receptors, immune system accessory molecules, adhesion molecules, adhesion receptor molecules, and adenosine-degrading enzymes.

### Claim 17 (depends on 16)

The oHSV of claim 16, wherein the cytokine is selected from interleukins, optionally any of interleukins 1-15; α, β, or γ-interferons; tumor necrosis factor; granulocyte macrophage colony stimulating factor (GM-CSF); macrophage colony stimulating factor (M-CSF); and granulocyte colony stimulating factor (G-CSF).

### Claim 18 (depends on 17)

The oHSV of claim 17, wherein the transgene is human interleukin 12 (hIL-12).

### Claim 19 (depends on 16)

The oHSV of claim 16, wherein the chemokine is selected from B7.1 and B7.2.

### Claim 20 (depends on 16)

The oHSV of claim 16, wherein the adhesion molecule is selected from ICAM-1, -2, and -3.

### Claim 21 (depends on 16)

The oHSV of claim 16, wherein the immune system accessory molecule is selected from neutrophil activating protein (NAP), macrophage chemoattractant and activating factor (MCAF), RANTES, and macrophage inflammatory peptides MTP-1a and MTP-1b.

### Claim 22 (depends on 16)

The oHSV of claim 16, comprising (i) a mutation that consists of a deletion of a region corresponding to the BstEII-EcoNI fragment of the BamHI x fragment of F strain of herpes simplex virus I, and (ii) an inactivating mutation in a γ34.5 neurovirulence locus, and optionally (iii) optionally an inactivating mutation elsewhere in the genome and/or (iv) a reporter gene like GFP or LacZ.

### Claim 23 (depends on 22)

The oHSV of claim 22, wherein the oHSV is G47Δ.

### Claim 24

An oncolytic herpes simplex virus (oHSV) comprising a promoter and an enhancer sequence comprising:
(SEQ ID NO: 16)
CTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCG
CTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCCCCGCTCCTCCCC
CCGCTCCTCCCCCCGCTCCTCCCCCCCCCGCTCCCGCGGCCCCGC
CCCCAACGCCCGCTCCTCCCCCCGCTCCCGCGGCCCCGCCCCCAA
CGCCCGCCGCGCGCGCGCACGCCGCCCTTGACTCACGGGGATTTC
CAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACC
AAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCAT
TGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAA
GCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTA
TCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTTACCGGC
GAAGGAGGGCCACC.

### Claim 25 (depends on 24)

The oHSV of claim 24, comprising (i) a mutation that consists of a deletion of a region corresponding to the BstEII-EcoNI fragment of the BamHI x fragment of F strain of herpes simplex virus I, and (ii) an inactivating mutation in a γ 34.5 neurovirulence locus, and optionally (iii) optionally an inactivating mutation elsewhere in the genome and/or (iv) a reporter gene like GFP or LacZ.

### Claim 26 (depends on 25)

The oHSV of claim 25, wherein the oHSV is G47Δ.

### Claim 27 (depends on 24)

The oHSV of claim 24, further comprising a human IL-12 transgene operably linked to the promoter and enhancer of SEQ ID NO:12.

### Claim 28

An oHSV comprising a human IL-12 expression cassette comprising SEQ ID NO:17, optionally wherein the oHSV is G47Δ.

### Claim 29 (depends on 15)

A method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of the oHSV of claim 15.

### Claim 30 (depends on 29)

The method of claim 29, wherein the cancer is a solid tumor.

### Claim 31 (depends on 30)

The method of claim 30, wherein the solid tumor is a nervous system tumor, optionally an astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioma, glioblastoma, ependymoma, schwannoma, neurofibrosarcoma, neuroblastoma, pituitary tumor, or medulloblastoma.

### Claim 32 (depends on 31)

The method of claim 31, wherein the nervous system tumor is a glioblastoma.

### Claim 33 (depends on 32)

The method of claim 32, wherein the solid tumor is melanoma, prostate carcinoma, renal cell carcinoma, pancreatic cancer, breast cancer, lung cancer, colon cancer, gastric cancer, fibrosarcoma, squamous cell carcinoma, neurectodermal, thyroid tumor, lymphoma, hepatoma, mesothelioma, or epidermoid carcinoma cells.

### Claim 34 (depends on 33)

The method of claim 33, wherein the breast cancer is triple negative breast cancer.

### Claim 35 (depends on 29)

The method of claim 29, further comprising administering an immunomodulator, optionally comprising one or more immune checkpoint inhibitors (ICIs) and/or inhibitors of the adenosine pathway.

### Claim 36 (depends on 35)

The method of claim 35, wherein the one or more ICIs are selected from an antibody that binds to PD-1, CD40, PD-L1, Tim3, Lag3, CTLA-4, or T-cell immunoglobulin and ITIM domains (TIGIT).

### Claim 37 (depends on 36)

The method of claim 36, wherein the one or more ICIs comprise an anti-PD-1 antibody and an anti-CTLA-4 antibody.

### Claim 38

A method of treating glioblastoma in a subject, the method comprising administering to the subject a G47Δ oncolytic herpes simplex virus (oHSV) comprising a promoter and an enhancer sequence, wherein the enhancer sequence comprises from six to 24 DR2 repeat sequence units (CGCTCCTCCCCC (SEQ ID NO:7), preferably wherein the enhancer and promoter sequence comprises SEQ ID NO:16, in combination with an anti-PD-1 antibody and an anti-CTLA-4 antibody.

### Claim 39 (depends on 38)

The method of claim 38, wherein the oHSV comprises SEQ ID NO:1, or a sequence at least 80%, 90%, 95%, or 99% identical to nucleotides 93-2490 of SEQ ID NO:1, or to nucleotides 416-2490 of SEQ ID NO:1.

### Claim 40 (depends on 39)

The method of claim 39, wherein the oHSV is G47ΔhIL12A.

### Claim 41

A method of treating glioblastoma in a subject, the method comprising administering to the subject an oncolytic herpes simplex virus (oHSV) comprising a promoter and an enhancer sequence, wherein the enhancer sequence comprises from six to 24 DR2 repeat sequence units (CGCTCCTCCCCC (SEQ ID NO:7), preferably wherein the enhancer and promoter sequence comprises SEQ ID NO:16, in combination with an anti-PD-1 antibody and an anti-CTLA-4 antibody.

### Claim 42 (depends on 40)

The method of claim 40, wherein the oHSV is G207, G207-Us11, Δ68H-6, or MG18L.

### Claim 43 (depends on 40)

The method of claim 40, wherein the oHSV comprises SEQ ID NO:1, or a sequence at least 80%, 90%, 95%, or 99% identical to nucleotides 93-2490 of SEQ ID NO:1, or to nucleotides 416-2490 of SEQ ID NO:1.
